Efficacy of Melatonin and Pentoxifylline combination therapy in treatment of endotoxin induced hepatic dysfunction in white albino mice
Despite major expansion and elaboration in treatment protocols of septic patients, mortality rate is still very high due to multiple organ damage including hepatotoxicity. We in study evaluated the role of two strong anti-inflammatory agents, melatonin and pentoxifylline, as a combined treatment in lipopolysaccharide induced hepatic dysfunction in white albino mice.
Material and Methods:
Endotoxemia was reproduced in white albino mice through intraperitoneal administration of lipopolysaccharide (LPS) of serotype E.Coli. Therapeutic potential of the both melatonin and pentoxifylline alone and as combined therapy was adjudged by administering agents 2 hours after LPS delivering. The extent of liver damage was evaluated via serum alanine aminotransferases (ALT) and aspartate aminotransferase (AST) estimation along with histopathological examination of liver tissue.
Results: Lipopolysaccharide administration (Group 2) resulted in marked hepatotoxicity as evident by statistically raised serum ALT ((p≤0.01) and AST (p≤0.01) at the end of experimentation. Also liver cross section examination showed marked distortion of liver parenchyma. Melatonin (Group 3) was prosperous in aversion of LPS invoked hepatotoxicity as proved by lessening of augmented ALT (p≤0.01) and AST (p≤0.01) along with restoration of pathological changes on liver sections (p≤0.05). Pentoxifylline generated similar results and serum ALT, AST and histological alteration abated considerably (p≤ 0.05).Combination therapy in animals of Group 5 also tapered LPS evoked hepatic dysfunction statistically considerably.
Conclusion: Melatonin and pentoxifylline alone and as combination therapy as effective in countering LPS induced hepatotoxicity. However the combination therapy did not yield synergistic effects.
Lipopolysaccharides, Endotoxin, Hepatotoxicity, Melatonin, Pentoxifylline.
2. Stoller J, Halpin L, Weis M, Aplin B, Qu W, Georgescu C, Nazzal M. Epidemiology of severe sepsis: 2008-2012. Journal of critical care. 2016 Feb 1;31(1):58-62.
3. Finfer S, Machado FR. The Global Epidemiology of Sepsis. Does It Matter That We Know So Little? Am J Respir Crit Care Med. 2016 Feb 1;193(3):228-30.
4. Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Critical care clinics. 2018 Jan 1;34(1):63-80.
5. Strnad P, Tacke F, Koch A, Trautwein C. Liver—guardian, modifier and target of sepsis. Nature reviews Gastroenterology & hepatology. 2017 Jan;14(1):55.
6. Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 2009;61:383-410. 10.1016/S1734-1140(09)70081-7
7. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007 Jan;42(1):28-42. doi: 10.1111/j.1600-079X.2006.00407.x. PMID: 17198536.
8. Ji MH, Xia DG, Zhu LY, Zhu X, Zhou XY, Xia JY, Yang JJ. Short-and long-term protective effects of melatonin in a mouse model of sepsis-associated encephalopathy. Inflammation. 2018 Mar;41(2):515-29.
9. Wu JY, Tsou MY, Chen TH, Chen SJ, Tsao CM, Wu CC. Therapeutic effects of melatonin on peritonitis‐induced septic shock with multiple organ dysfunction syndrome in rats. Journal of pineal research. 2008 Aug;45(1):106-16.
10. Zhang J, Wang L, Xie W, et al. Melatonin attenuates ER stress and mitochondrial damage in septic cardiomyopathy: A new mechanism involving BAP31 upregulation and MAPK-ERK pathway. J Cell Physiol 2020;235:2847-2856. 10.1002/jcp.29190
11. Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, Ferreira Seiva FR, Martinez M, Fávaro WJ et al. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. BMC Cancer. 2015 Feb 6;15:34. doi: 10.1186/s12885-015-1032-4. PMID: 25655081; PMCID: PMC4322437.
12. da Rosa DP, Forgiarini LF, Silva MB, et al. Antioxidants inhibit the inflammatory and apoptotic processes in an intermittent hypoxia model of sleep apnea. Inflamm Res 2015;64:21-9. 10.1007/s00011-014-0778-5
13. Biancatelli RM, Berrill M, Mohammed YH, Marik PE. Melatonin for the treatment of sepsis: the scientific rationale. Journal of Thoracic Disease. 2020 Feb;12(Suppl 1):S54.
14. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010 Jul;34(1):10-6. doi: 10.1097/SHK.0b013e3181cdc3e2. PMID: 19997047
15. Schüller SS, Wisgrill L, Herndl E, Spittler A, Förster-Waldl E, Sadeghi K, Kramer BW, Berger A. Pentoxifylline modulates LPS-induced hyperinflammation in monocytes of preterm infants in vitro. Pediatric research. 2017 Aug;82(2):215-25.
16. Hendawy N. Pentoxifylline attenuates cytokine stress and Fas system in syngeneic liver proteins induced experimental autoimmune hepatitis. Biomedicine & Pharmacotherapy. 2017 Aug 1;92:316-23.
17. Wang, W., Zolty, E., Falk, S., Basava, V., Reznikov, L., & Schrier, R. (2006). Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol-Renal, 291(5), F1090-F1095.
18. Harikrishnan VS, Hansen AK, Abelson KS, Sørensen DB. A comparison of various methods of blood sampling in mice and rats: Effects on animal welfare. Laboratory animals. 2018 Jun;52(3):253-64.
19. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 2000 Jan;31(1):241-6.
20. .( Russell JA, Rush B, Boyd J. Pathophysiology of septic shock. Critical care clinics. 2018 Jan 1;34(1):43-61.)
21. Ersoy OF, Özkan N, Özsoy Z, Kayaoğlu HA, Yenidoğan E, Çelik A, Özuğurlu AF, Arabacı Çakır E, Lortlar N. Effects of melatonin on cytokine release and healing of colonic anastomoses in an experimental sepsis model. Ulus Travma Acil Cerrahi Derg. 2016 Jul 1;22(4):315-21.
22. Acuña-Castroviejo D, Rahim I, Acuña-Fernández C, Fernández-Ortiz M, Solera-Marín J, Sayed RK, Díaz-Casado ME, Rusanova I, López LC, Escames G. Melatonin, clock genes and mitochondria in sepsis. Cellular and molecular life sciences. 2017 Nov;74(21):3965-87.
23. Hu, W., Deng, C., Ma, Z., Wang, D., Fan, C., Li, T., Di, S., Gong, B., Reiter, R. J., and Yang, Y. (2017) Utilizing melatonin to combat bacterial infections and septic injury. British Journal of Pharmacology, 174: 754– 768. doi: 10.1111/bph.13751).
24. Chen J, Xia H, Zhang L, et al. Protective effects of melatonin on sepsis-induced liver injury and dysregulation of gluconeogenesis in rats through activating SIRT1/STAT3 pathway. Biomed Pharmacother 2019;117:109150. 10.1016/j.biopha.2019.109150
25. Speer EM, Diago-Navarro E, Ozog LS, Raheel M, Levy O, Fries BC. A neonatal murine Escherichia coli sepsis model demonstrates that adjunctive pentoxifylline enhances the ratio of anti-vs. pro-inflammatory cytokines in blood and organ tissues. Frontiers in immunology. 2020 Sep 23;11:2249.
26. Speer EM, Dowling DJ, Ozog LS, Xu J, Yang J, Kennady G, Levy O. Pentoxifylline inhibits TLR-and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns. Pediatric research. 2017 May;81(5):806-16
27. Luo M, Dong L, Li J, Wang Y, Shang B. Protective effects of pentoxifylline on acute liver injury induced by thioacetamide in rats. International journal of clinical and experimental pathology. 2015;8(8):8990.
28. Zaitone, S., Hassan, N., El-Orabi, N., & El-Awady, E. S. (2011). Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease. Eur J Pharmacol, 662(1), 70-77.
29. Noyan, T., Kömüroğlu, U., Bayram, I., & Şekeroğlu, M. R. (2006). Comparison of the effects of melatonin and pentoxifylline on carbon tetrachloride-induced liver toxicity in mice. Cell Biol Toxicol, 22, 381-391
Copyright (c) 2022 Ammara Khan, Ayesha Afzal, Zahid Azam, Saima Rafique
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.